A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer

Warde, Padraig; O’Sullivan, Brian; Aslanidis, Julie; Kroll, B.; Lockwood, Gina; Waldron, John; Payne, David G.; Bayley, Andrew; Ringash, Jolie; Kim, John; Liu, Fei‐Fei; Maxymiw, W.G.; Sprague, S.; Cummings, Bernard

doi:10.1016/s0360-3016(02)02890-0

Cited by 100 publications

(52 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar schedule of pilocarpine administration was followed in our study. Pilocarpine was well tolerated by all patients of study group and side effects were mild as reported in other studies [7][8][18][19]. Discontinuation of pilocarpine because of side effects was not required in any of the patients.…”

Section: Discussionsupporting

confidence: 67%

Pilocarpine and Prevention of Radiation Induced Xerostomia in HNSCC

Atri¹

2014

JCPCR

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 67%

Pilocarpine and Prevention of Radiation Induced Xerostomia in HNSCC

Atri¹

2014

JCPCR

View full text Add to dashboard Cite

“…Furthermore, it has no effect on tumor regrowth [111]. A total number of 13 studies assessed the protective effect of oral pilocarpine HCl being administered concomitantly with radiotherapy in patients with head and neck cancer; 11 randomized controlled trials (one was cross-over with patients as their own controls) [97,110,[112][113][114][115][116][117][118][119][120] and two controlled before and after studies [121,122]. Xerostomia was evaluated in all studies, whereas salivary gland function was measured in six studies, parotid and submandibular/ sublingual salivary flow rates (unstimulated and stimulated) in three studies [110,112,120], unstimulated whole salivary flow rates in four studies [97,116,117,119], and stimulated whole salivary flow rates in three studies [116,117,119] and salivary scintigraphy in one study [122].…”

Section: Treatment With Pilocarpine After Radiation Therapymentioning

confidence: 99%

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Jensen

Pedersen

Vissink

et al. 2010

Support Care Cancer

222

179

View full text Add to dashboard Cite

There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.

show abstract

“…The prophylactic use of systemic sialogogues for radiationinduced xerostomia is widely reported in the literature [28][29][30][31][32][33][34][35][36]. These drugs are defined as systemic stimulants of salivary gland function by acting directly on the parasympathetic nervous system [19].…”

Section: Systemic Sialogoguesmentioning

confidence: 99%

Clinical features and preventive therapies of radiation-induced xerostomia in head and neck cancer patient: a literature review

et al. 2017

View full text Add to dashboard Cite

Xerostomia or dry mouth is one of the most common and disturbing adverse effects following radiotherapy for head and neck cancer (HNC). This complication strongly increases the risk for dental caries, difficulties with chewing, swallowing and sleep disorders with significant impact on patients' quality of life. Current treatment approaches of xerostomia are often difficult and bring in many cases no substantial relief for the patient. This paper discusses the clinical features and current knowledge of xerostomia prevention in order to evaluate the real possibilities of reducing the incidence and severity of this complication in HNC patients. Salivary gland cytoprotectants (amifostine), muscarinic agonist stimulation (pilocarpine and bethanechol), salivary gland-sparing radiation technique (intensity-modulated radiotherapy-IMRT), surgical relocation of the submandibular gland, intraoral stent and stem cell transplantation are promising techniques that are discussed in this study.

show abstract

A Phase III placebo-controlled trial of oral pilocarpine in patients undergoing radiotherapy for head-and-neck cancer

Cited by 100 publications

References 16 publications

Pilocarpine and Prevention of Radiation Induced Xerostomia in HNSCC

Pilocarpine and Prevention of Radiation Induced Xerostomia in HNSCC

A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact

Clinical features and preventive therapies of radiation-induced xerostomia in head and neck cancer patient: a literature review

Contact Info

Product

Resources

About